Nivix Pharmaceuticals Signs IPO Agreement with Muktinath Capital

Nivix Pharmaceuticals Ltd. has signed an agreement with Muktinath Capital on 2082/04/07 to manage the issuance of 1,375,000 ordinary shares for the public. The agreement was signed by Managing Director Indra Baniya and Muktinath CEO Kabindra Dhoj Joshi, with key officials, including Chairman Kalidas Paudel, also present.

Established in 2074 and converted to a public limited company in 2081, Nivix currently produces and markets 56 types of medicines, mainly for heart, diabetes, respiratory, liver, and digestive issues, while also planning to expand its product range through ongoing research.